Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model
Oncology Reports · 2025
DOI: 10.3892/or.2025.9014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2025. Verfasst von Sharmineh Mansoori und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Akademiska Hospital (Uppsala University Hospital), 751 85 Uppsala, Sweden. Hauptthemen laut MEDLINE: Mebendazole, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Akademiska Hospital (Uppsala University Hospital), 751 85 Uppsala, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Zitieren
APA
Mansoori, S., Blom, K., Andersson, C., Fryknäs, M., Larsson, R., & Nygren, P. (2025). Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model. Oncology Reports. https://doi.org/10.3892/or.2025.9014
Vancouver
Mansoori S, Blom K, Andersson C, Fryknäs M, Larsson R, Nygren P. Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model. Oncology Reports. 2025. doi:10.3892/or.2025.9014
BibTeX
@article{Mansoori2025,
author = {Mansoori, Sharmineh and Blom, Kristin and Andersson, Claes and Fryknäs, Mårten and Larsson, Rolf and Nygren, Peter},
title = {Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model},
journal = {Oncology Reports},
year = {2025},
doi = {10.3892/or.2025.9014}
}
EUVIMED